Publicaciones en colaboración con investigadores/as de Pitié-Salpêtrière Hospital (67)

2023

  1. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  2. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  3. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  4. Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

    Leukemia, Vol. 37, Núm. 2, pp. 388-395

  5. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  6. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 6, pp. 1706-1717

  7. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group

    The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311

  8. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia

    Future Oncology, Vol. 19, Núm. 5, pp. 345-353

  9. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia

    Seminars in Hematology

  10. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients

    Seminars in Hematology

  11. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients

    Seminars in Hematology

  12. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management

    Seminars in Hematology

  13. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials

    Seminars in Hematology

  14. SARS-CoV-2 Infection in Patients with Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study

    HemaSphere

  15. Symptomatic vs. non-symptomatic device-related thrombus after LAAC: a sub-analysis from the multicenter EUROC-DRT registry

    Clinical Research in Cardiology, Vol. 112, Núm. 12, pp. 1790-1799

  16. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020

  17. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106

  18. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 11, pp. 3439-3451

2022

  1. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial

    European Heart Journal, Vol. 43, Núm. 29, pp. 2783-2797

  2. Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry

    Clinical Research in Cardiology, Vol. 111, Núm. 11, pp. 1276-1285